We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Current Opportunities
San Francisco, CA
Posted: 26 Mar 2024Closes: 22 Sep 2024 16:01
Posted: 26 Mar 2024Closes: 22 Sep 2024 16:01
San Francisco, CA
Posted: 18 Mar 2024Closes: 14 Sep 2024 16:05
Posted: 18 Mar 2024Closes: 14 Sep 2024 16:05
San Francisco, CA
Posted: 18 Mar 2024Closes: 14 Sep 2024 16:04
Posted: 18 Mar 2024Closes: 14 Sep 2024 16:04
San Francisco, CA
Posted: 04 Mar 2024Closes: 31 Aug 2024 11:31
Posted: 04 Mar 2024Closes: 31 Aug 2024 11:31
CMC Operations, Director
89bio
89bio
San Francisco, CA
Posted: 27 Feb 2024Closes: 25 Aug 2024 12:23
Posted: 27 Feb 2024Closes: 25 Aug 2024 12:23
San Francisco, CA
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:37
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:37
San Francisco, CA
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:33
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:33
San Francisco, CA
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:29
Posted: 26 Jan 2024Closes: 24 Jul 2024 11:29
San Francisco, CA
Posted: 12 Jan 2024Closes: 10 Jul 2024 12:49
Posted: 12 Jan 2024Closes: 10 Jul 2024 12:49
San Francisco, CA
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:19
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:19
San Francisco, CA
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:12
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:12
San Francisco, CA
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:12
Posted: 08 Jan 2024Closes: 06 Jul 2024 10:12